CAMBRIDGE, November 2, 2026 — MIT scientists have developed a method to control the density of cancer targets displayed on engineered nanoparticles, a change that significantly strengthened immune responses in mice. The study, published in Advanced Healthcare Materials, demonstrates that adjusting how densely antigens are packed onto a viral scaffold can improve protection against melanoma and colorectal tumors.
Precision in Vaccine Design
The research team used a modified bacteriophage called M13 as the backbone for the vaccine platform. M13 is a virus that infects bacteria and is harmless to humans. By engineering this particle, researchers created a nanofiber approximately 200 nanometers in length that can be coated with specific cancer antigens. The key innovation lies in the ability to precisely control the density of these antigens on the particle’s surface.
Shengnan Huang, a research scientist at the Koch Institute for Integrative Cancer Research and the study’s lead author, focused on the relationship between antigen dosage and immune response. “The antigen is the specific target we want to initiate the immune response against, which means we have to ensure the right dose of antigen to make sure that we can have a strong immune response,” Huang said. Previous work by the lab suggested that density mattered, but this study provided a method to tune that density directly.
The team modified a major capsid protein called pVIII to attach antigens. By adding negatively charged amino acids and introducing regulatory mutations, they adjusted the proportion of antigen-bearing proteins on the particle. This allowed them to display antigens at densities ranging from about 6% to 70.4% of the major coat proteins. In physical terms, this corresponds to roughly 36 to 420 antigen-bearing copies per particle. The highest density required a trade-off, as particle yield fell substantially during manufacturing, but the immune benefits in animal models were clear.
Stronger Defense in Mouse Models
In laboratory experiments, mice vaccinated with higher-density particles showed improved protection when later challenged with tumor cells. The study tested two scenarios: melanoma and colorectal cancer models. In the melanoma model, mice receiving the higher-density vaccine were less likely to develop tumors after exposure to cells carrying the same antigen. They also produced more T cells specifically targeting the cancer-associated protein.
The results were particularly notable in the colorectal model. The team used a neoantigen called ADPGK, a protein found specifically in colon tumors in the mouse model. Neoantigens arise from genetic changes in cancer cells and help the immune system distinguish tumors from healthy tissue. The study reported a roughly sevenfold higher fraction of neoantigen-specific T cells in these animals compared to controls.
Angela Belcher, the James Mason Crafts Professor of Biological Engineering and Materials Science and Engineering at MIT and the senior author, noted the modular nature of the platform. “The great thing about this is that it’s modular and we could switch out different antigens on demand, so you could design it to be patient-specific and target a known antigen for a particular kind of cancer,” Belcher said. This modularity is central to the potential for personalized medicine, where vaccines could be tailored to the unique genetic profile of an individual patient’s tumor.
A Platform Built on Decades of Work
This work builds on more than 20 years of research by Belcher’s lab, which has deployed M13 bacteriophages in various applications. Previously, the lab engineered these viruses to self-assemble into nanoscale scaffolds for use in batteries, semiconductors, solar cells, and catalysts. The current study repurposes that toolkit for medical applications, specifically vaccine therapeutics.
“We’re taking this toolkit that we’ve worked on and developed over decades and formatting it to be specific for vaccine therapeutics,” Belcher said. “Some of the lessons learned from making batteries and all these other things are now being fine-tuned to make personalized vaccines.” The transition from materials science to biomedicine highlights how foundational research in one field can yield unexpected applications in another.
Another advantage of the M13 platform is its inherent adjuvant activity. The single-stranded DNA of the virus activates a pathway called Toll-like receptor 9, or TLR9, which stimulates the innate immune system. This means the particle acts as its own immune booster, potentially eliminating the need for a separate adjuvant in the vaccine formulation. The researchers found that dendritic cells, which help activate T cells, were more likely to take up particles displaying higher antigen densities, further explaining the stronger immune response.
Early Findings and Next Steps
It is important to note that these results come from laboratory experiments and small mouse studies, not clinical trials. The study vaccinated mice before researchers injected tumor cells, testing protection against a future challenge. This is a preventive model, similar to how traditional vaccines work for infectious diseases. Whether the same density adjustments improve the treatment of established tumors in humans requires further testing.
The researchers emphasize that the platform could support personalized cancer vaccines, but it has not yet established effectiveness in people. The current data shows promise in controlling immune response strength, but translating this to human patients involves complex biological factors that are not fully captured in mouse models. Clinical trials will be necessary to determine if this approach is safe and effective for human cancer patients.
For patients currently dealing with cancer, this research represents a potential future direction rather than an immediate treatment option. The encouraging part is the precision with which the immune system can now be targeted, offering a path toward vaccines that are tailored to individual tumors. However, patients should continue to follow the treatment plans recommended by their medical teams. Early findings suggest a promising mechanism, but rigorous clinical validation is the next essential step. If you or a loved one is facing a cancer diagnosis, talk to your doctor or oncologist about current treatment options and clinical trials that may be available.
Sources
- MIT scientists create nanoparticles to deliver cancer vaccines tailored to each patient
- MIT engineers create nanoparticles for delivering personalized cancer vaccines
- MIT scientists create nanoparticles to deliver cancer vaccines tailored to each patient
- MIT's viral nanofiber could help create personalized cancer vaccines
- Nanoscale particle shows potential as customizable delivery vehicle for personalized cancer vaccines
Photo: National Institute of Standards and Technology (Public domain)
